Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program December 3, 2025
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4 December 2, 2025
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity November 18, 2025
